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Abstract: Chiral HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are of great
interest since one enantiomer is often more potent than the corresponding counterpart against
the HIV-1 wild type (WT) and the HIV-1 drug resistant mutant strains. This review exemplifies the
various studies made to investigate the effect of chirality on the antiretroviral activity of top HIV-1
NNRTI compounds, such as nevirapine (NVP), efavirenz (EFV), alkynyl- and alkenylquinazolinone
DuPont compounds (DPC), diarylpyrimidine (DAPY), dihydroalkyloxybenzyloxopyrimidine
(DABO), phenethylthiazolylthiourea (PETT), indolylarylsulfone (IAS), arylphosphoindole (API)
and trifluoromethylated indole (TFMI) The chiral separation, the enantiosynthesis, along with the
biological properties of these HIV-1 NNRTIs, are discussed.
Keywords: chirality; HIV-1; reverse transcriptase; non-nucleoside inhibitor
1. Introduction
Human immunodeficiency virus type 1 (HIV-1) is the etiological agent of acquired immune
deficiency syndrome (AIDS), a global pandemic disease which has claimed the lives of more than
34 million people so far. In 2014 alone, AIDS caused about 1.2 million deaths worldwide [1]. The
treatment of HIV infected people is based on antiretroviral therapy (ART), also known as highly active
antiretroviral therapy (HAART), which combines three or more drugs that suppress HIV replication [1].
ART can play an important role in preventing HIV transmission and post-exposure prophylaxis [2].
Thus far, there are no vaccines available for HIV. However, recent studies have shown that a vaccine
can reduce the risk of HIV infection, and other novel vaccine strategies include broadly neutralizing
antibodies that target a wide range of HIV strains [3,4]. Novel HIV vaccine candidates that are being
developed, have shown to elicit strong protective antibody responses across the spectrum of HIV-1
strains. In the absence of such a vaccine, the nucleoside reverse transcriptase inhibitors (NRTI) can be
an option for pre-exposure prophylaxis in preventing HIV infection in HIV-negative individuals [5].
The approved antiretroviral arsenal includes about thirty drugs falling in five main classes
which control the levels of HIV-1 by targeting different steps of the viral life cycle. The drugs
are nucleoside reverse transcriptase inhibitors that also include nucleotide agents, non-nucleoside
reverse transcriptase inhibitors [6], viral maturation inhibitors (protease inhibitors), viral entry
inhibitors including fusion inhibitors and co-receptor antagonists, and integration inhibitors [7].
These antiretroviral drugs may be administered singly or combined into multi-drug pharmaceutical
formulations [8]. Targeting different steps of the viral life cycle has proven to be a successful strategy
in the management of the HIV infection. The ART treatments suppress the viral replication and
delay the progression of HIV infection, in particular in early stages of the disease. In most patients
treated with ART therapy, the levels of plasma viremia remain below the limit of detection for at least
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six months [8]. However, some issues are still pending, namely the emergence of resistance even among
drugs belonging to the same class (cross resistance), unwanted side effects and toxicity problems,
which lead to failing to comply with the prescribed ART regimens [9–15]. Therefore there is a pressing
need for new potent antiretroviral drugs with improved tolerability and better resistance profiles.
NNRTIs of HIV-1 are key drugs for the treatment of AIDS [16–18]. Thanks to their specificity
for HIV-1, which makes them very selective inhibitors, NNRTIs became standard components of
ART regimens [19,20]. NNRTIs show a wide variety of different structures. Despite the structural
diversity, the NNRTIs show high specificity for the HIV-1 reverse transcriptase (RT), as they do not
inhibit the HIV-2. The RT is a heterodimeric enzyme formed by the subunits p66 and p51 [21,22]. The
NNRTIs bind to a common allosteric site of the RT, the non-nucleoside binding site (NNBS), that is
a hydrophobic pocket located just 10 Å from the DNA polymerase active site, formed by residues
Leu100, Lys101, Lys103, Val106, Thr107, Val108, Val179, Tyr181, Tyr188, Val189, Gly190, Phe227, Trp229,
Leu234, Pro236 and Tyr318 in the p66 palm subdomain, and Glu138 of p51 [23]. The thumb is mainly
in a closed position in unliganded RT. Upon NNRTI binding, the thumb moves to an upright position.
The binding of the NNRTI to the RT may result in thumb mobility [18] and conformational changes
of the catalytic site [24], hampering of the primer bond [25] and the thumb/finger connection [26],
resulting in impairment of the enzyme catalysis. Some amino acids that make up the NNBS are part
of the RT primer grip, the residues 227 and 235 in the palm domain position the primer end. Finally,
the NNBS and the shift of the three-stranded β-sheet affect the position of residues D185 and D186
that coordinate the Mg2+ ions in the catalytic site [27]. Such changes may re-position the dNTP and
impair chain elongation.
The ART regimens for a treatment-naive patient combines three or more antiretroviral drugs,
generally two nucleoside reverse transcriptase inhibitors with a third non-nucleoside antiretroviral
drug: a reverse transcriptase inhibitor, a protease inhibitor or an integrase strand transfer inhibitor [28].
NNRTI-based regimes increase age of patients living with HIV, have relatively few adverse [10]
effects and better pharmacokinetic properties [29]. Major limitations of NNRTIs are the emergence of
resistance and cross-resistance as a result of single and double amino acid mutations inside the NNBS
of HIV-1 RT which hamper the binding of the NNRTI [30].
Chiral compounds often exhibit considerably different biological activities due to the highly
specific nature of the chiral ligand-recognition site interaction [31,32]. The enantiomers, along with the
corresponding racemates, require specific biological, pharmacological and toxicological studies before
being launched in clinical practice [33]. Since 1992, the US Food and Drugs Administration (FDA) [34]
and the European Committee for Proprietary Medicinal Products have required manufacturers to
research and characterize each enantiomer in all drugs proposed to be marketed as a mixture. Therefore,
racemic drugs ceased to be a rational commercial option, and academia and drug firms have been
developing synthetic procedures and chiral separation techniques to achieve enantiomerically pure
biologically active compounds [35].
The enantioselectivity plays an important role for the binding of antiviral agents to the asymmetric
RT enzyme of HIV-1. The RT can incorporate enantiomeric nucleotides of both D and L series
(while cell DNA polymerase cannot) as well as triphosphate analogues of L-nucleosides [36,37].
For example, the 31-hydroxyl group of L-(β)-ribose is responsible for chiral discrimination between
D- and L-enantiomers of deoxy- and dideoxy-nucleoside analogues [38]. The L-enantiomer of
21,31-dideoxycytidine (DDC) and its 5-fluoro congener (L-FDDC) showed to inhibit selectively HIV-1
in vitro [39]. β-L-5-fluorocytosine derivatives were found to be potent anti-HIV compounds [40];
(´)-FTC was also found to be a potent inhibitor of hepatitis B virus replication, while the D-isomer
was found to be considerably less active against hepatitis B virus [41]. This paper provides an updated
review that covers recent research on resistance to NNRTIs of approved and investigational drugs.
We focused particularly on the chemical modification of chiral atoms that to our knowledge was not
exhaustively reviewed.
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2. Nevirapine
Nerivapine (1, NVP) (Viramune) was designed and synthesized by Merluzzi and co-workers at
Boehringer Ingelheim Pharmaceutical Inc. [42,43] and approved in 1996 by the FDA for the treatment
of AIDS/HIV infection in combination with NRTIs. NVP is well tolerated, but, like other NNRTIs,
leads to rapid development of drug resistance due to drug-specific amino acid mutations in the
NNBS of the RT [44–46]. Moreover, NVP causes cross resistance to drugs belonging to the NNRTI
class. X-ray studies [47] of NVP revealed a butterfly-like conformation formed by intersection at
an angle of 121˝ of two planes of up- or downwards pyridyl rings from the central diazepinone
nucleus (Scheme 1). The pendant 11-cyclopropyl ring lays almost perpendicularly to the plane of the
diazepinone, opposite to the two pyridyl rings [48]. The crystal structure shows small deformations
of NVP, whereas the butterfly-like active conformation is preserved in the complexes of NVP with
the HIV-1 RT [49]. The lack of plane of symmetry and the flexibility of the diazepinone allows NVP
to exist as a mixture of atropisomeric enantiomers with relatively slow interconversion, despite the
absence of stereogenic centers, in the presence of a quaternary stereogenic center by memory of
chirality [50]. NVP displayed 1H-NMR spectrum signals characteristic of a chiral compound at room
temperature. NMR and computational studies revealed that at room temperature the two enantiomeric
conformations interconvert with a barrier of about 76 kJ¨mol´1. Enantiomerisation half-life of NVP at
room temperature is in the order of seconds, is not an atropisomeric compound, and therefore cannot
exist as separable enantiomers [48].
Scheme 1. Butterfly model and enantiomeric conformers of nevirapine.
Recently NVP was isolated from 100 kg seeds of Cleome viscosa (Capparidaceae) with a yield
of 0.00397% [51]. It was suggested that plant might have biosynthesized NVP in response to either
some abiotic stress or that the compound has been triggered in response to some kind of endogenous
plant–pathogenic interaction. The crystal structure of the natural molecule was studied in order to
confirm its structure unequivocally. UV, IR, NMR of natural and synthetic NVP were found to be
identical. In contrast, the natural NVP isolated from the seeds of Cleome viscosa was shown to be
different from synthetic NVP through isotope ratio mass spectrometric (IRMS) analysis. The chiral
HPLC analysis of the natural and synthetic NVP showed a single peak in the HPLC chromatogram due
to the rapid interconversion of the molecule at room temperature. The synthetic acetyl derivative of
NVP at the carboxamide nitrogen showed two peaks in chiral HPLC confirming the racemic nature of
NVP. The N5-acetyl-NVP showed atropisomeric behavior by increasing the barrier to the N inversion
leading to the possibility of separating the two enantiomers.
3. Efavirenz
Delavirdine (Rescriptor) and efavirenz (2, EFV) (Sustiva) were successfully launched as anti-HIV-1
drugs in 1997 and 1998, respectively [52] (it should be noted that delavirdine is no longer used as
a component of ART treatments). EFV is the first-line drug of initial combination regimes for the
antiretroviral naive patients and as prophylaxis after exposure to HIV infection. EFV is potent and
tolerated but its use is limited by its low genetic barrier to development of resistance [53]. Recently,
EFV-based ART treatments have been classified in the alternative regimens category due to the
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development of serious CNS-related toxicities and a possible association with depression, aggressive
behavior and suicidality [28].
EFV (formerly L-743,726, DMP-266) was discovered by Merck Research Laboratories (West Point,
PA, USA, and Rahway, NJ, USA) [54,55]. The absolute configuration of EFV was determined from a
single crystal X-ray diffraction analysis of the (´)-camphanate imide derivative 4 of the racemate 3
(Scheme 2). Solving the structure resulted in the determination of the chiral site of the benzoxazin-2-one
ring in the S configuration. The (S)-enantiomer was found to be a potent inhibitor of HIV-1 WT in MT-4
cell culture with IC95 in the 1.5–3.0 nM range. It also exhibited antiviral activity with 95% inhibitory
concentrations of ď1.5 µM against a panel of HIV-1 NNRTI-resistant mutant viruses carrying single
amino acid substitution of the RT. Whereas, the (R)-enantiomer, obtained in a similar way, was inactive
in the in vitro RT inhibition assay [54].
Scheme 2. Early separation of (S)-efavirenz (EFV) from the racemic mixture 3.
Efficient synthetic processes for the production of EFV have been developed [56]. The presence of
a stereo center in EFV prompted the synthesis of stereospecific synthesis. The asymmetric addition
of acetylide to the trifluoromethylketone 5 was optimized by Thompson [57] by adding n-buthyl
lithium to a solution of (1R,2S)-N-pyrrolidinylnorephinephrine [58] and cyclopropylacetylene. This
reaction allowed the chiral complex to form that is required to obtain high (50:1) enantioselectivity.
Two equivalents of lithium alkoxide 6 and two equivalents of lithium acetylide 7 were required
to achieve full conversion. Mixtures of 6 and 7 reacted with 5 at low temperature to provide
high enantioselectivities. Lithium cyclopropylacetylide and lithium alkoxide formed mixtures of
tetramers [57]. The 4-methoxybenzyl group was removed with dichlorodicyanoquinone (DDQ) to
afford quantitatively the amine 9 (11.5:1 distereomeric) which was transformed to amino alcohol 10
with sodium methoxide. Finally the benzoxazinone ring was easily obtained by reaction of 10 with
phosgene to give EFV in excellent optical purity (enantiomeric excess (ee) >99.5%). This processed
analytically pure EFV in an overall yield of 62%, (Scheme 3) [59].
Alternatively, the chiral ligand 11 was treated with dimethylzinc followed by the addition of an
alcohol or carboxylic acid [60]. This solution was treated with 1.2 eq of chloromagnesium acetylide 12
and then with 13. The process provides EFV in kilogram scale in 95.2% yield and 99.3% ee (Scheme 4).
In 2013, Seetharamappa et al. reported the first chiral HPLC method for the separation of the
(R)- and (S)-enantiomers of EFV [61] by using commercially available chiral stationary phase (Chiralcel
OD-H). This efficient method was successfully applied for the evaluation of enantiomeric purity in
bulk and pharmaceutical formulations, and it was sensitive at the low detection limit of 65 ng/mL
for (R)-EFV. At the same time Singh et al. developed a rapid isocratic chiral ultra-performance liquid
chromatography (UPLC) method for the separation of the EFV enantiomers [62]. Good resolution was
achieved by normal phase UPLC using chiral column Chiracel OD-H (250 mm ˆ 4.6 mm) 5 µm using
n-hexane and isopropyl alcohol 9:1 as a mobile phase at column temperature of 30 ˝C and flow rate of
1.0 mL/min. This method was used to determine the amount of (R)-EFV in pure and pharmaceutical
formulations of (S)-EFV and led to detect and quantitate (R)-EFV to the levels of 249 ng/mL and
75 ng/mL, respectively.
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Scheme 3. Thompson enatioselective synthesis of efavirenz.
Scheme 4. Chen enatioselective synthesis of 10.
4. DuPont Compounds (DPC)
DuPont Pharm. Co. initiated a drug discovery program to identify expanded-spectrum NNRTIs
which possess increased potency toward K103N mutation [63,64]. The K103N mutation is the major
mutation detected in patients receiving EFV-containing treatments whose viral loads rebounded after
an initial response to the drug [65,66]. Identification of the alkynylquinazolinones DPC 961 (14) and
DPC 963 (15) and the alkenylquinazolinones DPC 082 (16) and DPC 083 (17) (Scheme 5) resulted
in potent NNRTIs with low nanomolar potency against HIV-1 WT and the K103N and L100I
single-mutation strains.
Scheme 5. Quinazolinone analogues of EFV.
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The enantiomers 14 and 15 were separated from the corresponding racemates by chiral HPLC.
The stereochemistry of 14 was determined using X-ray crystallography diffraction, and the absolute
stereochemistry of DPC 15 was inferred from the antiviral and enzyme data. The asymmetric
synthesis of 14 was achieved in three steps starting from keto-aniline 18 with an overall yield >55%.
The asymmetry was induced by the chiral auxiliary (R)-(+)-α-methylbenzylamine, utilizing a new
asymmetric 1,4-addition protocol [67]. The hemiaminal 21 in the presence of triethylamine (TEA) and
thionyl chloride at 0 ˝C rapidly generated intermediate 22 which was trapped at ´50 ˝C by an excess
of 12. The diastereomer 23 was obtained in 85% isolated yield and 92% diasteromeric excess. Finally,
dihydroquinazolinone 23 was converted into 14 with trifluoroacetic acid (Scheme 6).
Scheme 6. Magnus asymmetric synthesis of DPC 961.
As compared to benzoxaxinones, in the quinazolinone series, the stereochemistry of the quaternary
center is inverted [55,68]. Against the HIV-1 K103N mutant strain in HIV-1 infected cell assay,
DPC derivatives 14 (K103N IC90 = 10 nM) and 15 (K103N IC90 = 11 nM) were superior to EFV
(K103N IC90 = 64 nM), while the corresponding enantiomers exhibited virtually no activity. The olefin
derivatives 16 and 17 were as potent as 14 and 15, and all were either as potent as, or more potent than,
EFV. Most importantly, this potency profile was maintained against a panel of single- and double-HIV-1
strains carrying the K103N mutation [63].
A chiral method was developed to resolve the racemic mixtures and control the enantiomeric
purity of compounds 14 and 17 and to monitor for any chiral inversion in the drug substance and
in the tablet formulation during stability studies [69]. Chiralpak AD, Chirobiotic V, and Whelk-O
columns were evaluated with various nonaqueous mobile phases which were selected because of poor
water solubility of 14 and 17. The order of elution on the Whelk-O and the Chiralpak AD columns was
found to be affected by the degree of unsaturation of α carbon–carbon bond on the side chain, while
the stereoselectivity was negatively affected by the presence of an NH group next to the chiral center.
This method was able to detect the enantiomeric purity of 14 and monitor chiral inversion on stability.
Chirobiotic V column showed high stereoselectivity for 17 and specificity toward nonenantiomeric
impurities using a mobile phase composed of acetonitrile and methanol 90:10 (v/v).
5. DAPY
The story of the DAPY family started in 1987 with tetrahydro-imidazo-benzodiazepin-one (TIBO)
derivatives [20]. Despite notable chemical differences from other NNRTIs, the bound conformation
Cl-TIBO into the NNBS of the RT shared similarities to other NNRTIs [70]. For example, the 5-methyl
group of 9-Cl-TIBO (24) (Scheme 7) achieved spatial equivalence to the cyclopropyl group in NVP
(see Scheme 1) and the amide in α-APA and methyl in HEPT. Such spatial equivalence was achieved
by the (+)-(S)-Me enantiomer of 9-Cl-TIBO which was in agreement with the inspected stereospecificity
specification [20].
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Scheme 7. Structure of tetrahydro-imidazo-benzodiazepin-one (TIBO), α-anilino-phenyl-acetamide
(α-APA), Etravirine (ETR) and Rilpivirine (RPV), and horseshoe model.
After development, TIBO was discontinued due to complex chemical synthesis and poor
bioavailability, a new class of α-anilinophenylacetamido (α-APA) derivatives was discovered in 1991
by random screening [71]. A program of synthesis was subsequently initiated, aimed at enhancing the
anti-HIV potency of α-APA derivatives. The antiretroviral activity of α-APA derivatives was clearly
stereospecific. For example, (´)-(R)-25 (EC50 HIV-1IIIB = 33 nM in MT-4 infected cells) was 50-fold
more potent than the corresponding (+)-(S)-isomer (EC50 = 1700 nM). The stereospecificity seen for the
enantiomers of (´)-(R)-25 extended to derivatives of this series [72].
In 1993 evolution of α-APA to improve the spectrum against the HIV-1 mutant strains led
to the discovery of the extremely active imidoyl thiourea (ITU) class [73]. Incorporation of a
cyanoguanidine moiety resulted in diaryltrazine (DATA) derivatives which showed subnanomolar
potency vs. the wild-type HIV-1 (LAI strain) and low nanomolar potency against a battery of clinically
important HIV-1 mutants, but were inactive against the double mutant strains K103N-L100I and
K103N-Y181C [73]. As a further advance, the central triazine core was replaced with a pyrimidine
ring and the 2,6-dichlorobenzyl moiety with 2,4,6-trisubstituted aromatic groups to give the DAPY
series [74]. Chemical manipulation on the DAPY scaffold resulted in the discovery of etravirine
(ETR) (26) and rilpivirine (RPV) (27) (Scheme 7), two broad spectrum NNRTIs with good metabolic
stability and plasma levels. ETR (Intelence) and RPV (Edurant) were launched onto the market in
2008 and 2011, respectively. Crystallographic studies showed that ETR in complex with the HIV-1 RT
adopted the “horseshoe” binding conformation [75]. The dynamic adaptation of DAPY analogues
into the NNBS of the HIV-1 RT might explain for their ability to inhibit HIV-1 RT carrying resistance
mutations [76].
Chemical studies to improve the antiretroviral properties of DAPY compounds focused on wing II,
since wing I proved to be an indispensable pharmacophore. The influence of a cyano substituent on the
CH2 linkage to give CN-DAPYs was investigated [77]. The CN-CH2-DAPYs 28 which were synthesized
by condensation of 29 [78] with an appropriately substituted arylacetonitrile 30 in the presence of
sodium hydride, were assayed as racemic mixture (Scheme 8). Most derivatives inhibited the HIV-1
WT replication in the nanomolar range of concentration ((˘)-28a: R1 = H, R2 = Me, R3 = 2-F, EC50
HIV-1IIIB = 1.8 nM in MT-4 infected cells; EFV as reference compound: EC50 HIV-1IIIB = 3.5 nM) [77].
Further introduction of a hydrophilic hydroxyl group to the CH2 linker led to a structurally novel
CH(OH)-DAPYs 32. The synthesis of derivatives 32 was performed by air oxidation of 28 in presence
of NaH and subsequent NaBH4 reduction of the corresponding ketones 31 [79]. The most active
CH(OH)-DAPY compound ((˘)-32a: R1 = R2 = H, R3 = 2-Cl) inhibited the HIV-1 WT with an EC50 value
9 nM in MT-4 cells and the double K103N-Y181C HIV-1 mutant strain with EC50 = of 6200 nM (EFV:
EC50 HIV-1IIIB = 5 nM; EC50 HIV-1 K103N-Y181C = 443 nM) [80]. The racemate 32a was successfully
separated into the corresponding (+) and (´) enantiomers by supercritical fluid chromatography (SCF)
with ee >99% and purity >99%. Their absolute (R) and (S) configuration, respectively, was assigned by
the experimental electronic circular dichroism (ECD) spectrum and simulated ECD spectra calculated
by time-dependent density functional theory (TDDFT) calculations. The (+)-(R)-32a enantiomer
inhibited the HIV-1 WT with an EC50 of 5 nM and was 13-fold superior to the (´)-(S)-32a enantiomer.
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In contrast, the (´)-(S)-32a enantiomer was more potent than (+)-(R)-32a against the HIV-1 K103N-Y181
mutant strain and HIV-1 ROD strain (EFV: EC50 HIV-1IIIB = 5 nM, K103N-Y181C = 440 nM) [80].
According to the biological results, docking studies highlighted different binding poses of the
two enantiomers into the NNBS of the HIV-1 RT.
Scheme 8. CN-CH2-DAPY and CH(OH)-DAPY derivatives.
6. DABO and DAPY-DABO Hybrids
The dihydroalkyloxybenzyloxopyrimidine (DABO) family of HIV-1 NNRTIs have been developed
since 1992 [81]. As a further development, a series of DAPY-DABO hybrid compounds was synthesized
by linking the 4-cyanoaniline group typical in DAPY at the position 2 of the pyrimidine core and the
2,6-difluorobenzyl group peculiar in DABO at the position 6. These compounds were characterized
by the presence at position 4 of the pyrimidine of characteristic groups either DAPY or DABO series.
The DAPY-DABO hybrids showed nanomolar anti-HIV-1 activity in both enzymatic and cellular
assays [82]. Two racemic mixtures among the DABO and DAPY-DABO hybrids families were separated
by chiral HPLC on coated-type Chiralpak AD chiral stationary phase (CSP) using ethanol containing
0.1% of diethylamine as eluent. Because of unsuccessful X-ray crystal efforts, the stereochemical
information on the four chiral compounds was achieved by analyzing their chiroptical properties.
The (S) configuration was assigned to the first-eluted dextrorotatory enantiomers, (+)-(S)-33 and
(+)-(S)-33, and the (R) configuration was assigned to the second-eluted levorotatory (´)-(R)-34 and
(´)-(R)-34 counterparts [82] (Scheme 9). In both cellular and enzyme assays, the (R)-33 and (R)-34
enantiomers were significantly superior to the (S)-ounterparts (the racemates showed intermediate
potencies). Compound (R)-34 (EC50 HIV-1NL4´3 = 0.1 nM; EC50 K103N = 0.8 nM; EC50 Y181C = 31 nM;
EC50 Y188L = 7.1 nM; MT-4 infected cells; EFV: EC50 HIV-1NL4´3 = 7.3 nM, EC50 K103N = 340 nM;
EC50 Y181C = 10 nM; EC50 Y188L = 1600 nM) [83] exhibited better profile than (R)-33 in inhibiting the
cytopathic effect of HIV-1 strains in MT-4 cells. However, (R)-33 was generally less toxics reaching
higher selectivity index than (R)-34. In the RT enzymatic assays, (R)-34 was superior to (R)-33 against
the HIV-1 WT, K103N, V106A, and Y188L RTs, while (R)-33 more potent against the L100I and
Y181I RTs.
Scheme 9. DABO and DABO-DAPY hybrid derivatives.
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7. PETT
Phenethylthiazolylthiourea (PETT) HIV-1 NNRTI class was discovered by Bell [84] and
Cantrell [85] at Lilly research laboratories. In 2004, Uckun reported a number of chiral
thiourea derivatives in order to examine the effect of stereochemistry of these PETT derivatives
on HIV-activity [86,87]. A series of chiral PETT derivatives was prepared by condensing
thiocarbaimidazole derivatives with the respective chiral amines in anhydrous DMF. β-methyl
phenethylthiazolylthiourea derivatives (R)-35a–c with halogen (Br, Cl) or methyl substitutions
respectively at 5-position of the pyridine were the most potent against the HIV-1 rRT in vitro with
nanomolar inhibitory concentrations. (Scheme 10). On the contrary, the (S)-anantiomers showed
lower inhibition in the micromolar range of concentration. Similarly, only β-methyl thiazolyl
derivatives of the (R) series exhibited anti-HIV activity. (R)-35a–c compounds inhibited the HIV-1
strain HTLVIIIB in human PBMCs with EC50 values of 3 nM, <1 nM and 3 nM, respectively (EFV:
EC50 HIV-1IIIB = 1.5 nM) [86]. Molecular modeling studies showed that the (R) stereoisomers of
chiral halopyridyl and thiazolylthiourea compounds would fit the NNBS of the HIV-1-RT better than
their (S) enantiomers, mainly due to unfavorable interactions of the (S) compounds in the pocket of
the NNBS surrounding the Y181. In agreement with the β-methyl series, all the (R) enantiomers of
the chiral α-methylbenzylthiourea derivatives proved to be potent inhibitors of the HIV-1, whereas
their (S) counterparts were inactive. Against the HIV-1 rRT compound 36a achieved an activity of
1.6 µM and 36b of 1.2 µM. Both compounds inhibited the HIV-1 HTLVIIIB with EC50 of 10 nM; NVP:
EC50 = 34 nM [87].
Scheme 10. β-methyl-PETT and α-methylbenzylthiourea derivatives.
8. IAS
The indolylarylsulfone (IAS) story started in 1993, when Merck reported L-737,126 as a potent
and selective HIV-1 NNRTI with EC50 = 1 nM against HIV-1IIIB WT [88]. SAR studies of the IAS class
showed that the methyl groups at the positions 31,51 of the 3-phenylsulfonyl moiety of the indole
are a key structural requirement for an effective inhibition of the HIV-1 mutant strains [89]. IAS
derivatives containing a chiral center were synthesized by coupling of glycine/alanine amino acid
units to the 2-carboxyamide function. The aim was to improve the chemical interactions inside the
NNBS of the HIV-1 RT by remodeling of the substituents at indole-2-sidechain [90]. The initial results
prompted the synthesis of a new series of peptide-IAS derivatives by coupling of natural and unnatural
amino acids to the indole-2-carboxamide [91]. Such IASs exhibited potent inhibition of HIV-1 with
inhibitory activities comparable to EFV in CEM cells. To evaluate the influence of the chiral center
at the amino acid unit, three D,L racemic mixtures were separated by chiral HPLC. Against HIV-1
WT RT, the L and D enantiomers from the corresponding racemates showed negligible differences of
activity. Against the K103N mutation, two D-enantiomers were about five times more potent than
the corresponding L-enantiomers, while the third couple of enantiomers did not show any significant
difference of activity [91].
A new series of IAS derivatives was synthesized by coupling of the 2-carboxyamide with
appropriate benzyl- or phenylethylamines. These new IASs shared similar features that are specific of
ETR the presence of a pendant (third) aromatic ring [76]. To evaluate the influence of the asymmetric
center at the 1-phenylethyl moiety, the racemic mixture (R,S)-37 was separated using a chiral HPLC
equipped with the stainless-steel Chiralcel OD (250 mm ˆ 4.6 mm i.d. and 250 mm ˆ 10 mm i.d.)
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to give the pure enantiomers (R)-37 and (S)-37 (Scheme 11) [92]. Against the HIV-1NL4´3 strain, the
enantiomers (R) and (S) showed small differences of activity. In contrast, (R)-37 (EC50 K103N = 4.3 nM;
EC50 Y181C = 86 nM; EC50 Y188L = 193 nM; EFV: EC50 K103N = 130 nM; EC50 Y181C = 160 nM; EC50
Y188L = 760 nM, MT-4 infected cells) [93] was significantly more potent than (S)-37 against the panel
of mutant HIV-1 strains: 30-fold vs. the K103N, 40-fold vs. Y181C, >189-fold vs. Y188L, and >22-fold
vs. K103N-Y181C. Against the HIV-1 RTs, the enantiomers (R)-37 and (S)-37 were almost equipotent
against the HIV-1 WT RT, and (R)-37 (IC50 = 90 nM) was 104-fold more potent than (S)-37 against the
HIV-1 K103N mutated RT. Docking studies suggested that the difference in the observed inhibitory
activities of (R)-37 and (S)-37 could be due to kinetic rather than affinity differences: while (R)-37 was
able to seal the binding pocket, (S)-37 left the site accessible to water, leading to a negative effect on the
binding kinetic of this inhibitor.
Scheme 11. Structures of IASs 37 and 38. Binding mode of (R)-38 (green) into the NNBS of the K103N
RT: the surface shows shape and position of the methyl group following the induced fit model.
A new series of IAS derivatives was designed addressing the strategy of the additional third cyclic
moiety [93]. The racemic mixture (R,S)-38 was directly separated by enantioselective HPLC using the
cellulose derived Chiralcel OD chiral stationary phase (CSP) and n-hexane/ethanol 1:1 as a mobile
phase. The optimized analytical enantioselective method was scaled-up to a semipreparative level to
obtain milligram amounts of the pure enantiomers for screening. The stereochemical characterization
of (S)-38 and (R)-38 was performed by circular dichroism (CD) correlation using the (R)-37 and
(S)-37 pure enantiomers as reference samples. The (R) configuration was empirically assigned to the
more retained enantiomer on the Chiralcel OD CSP, and the (S) configuration, to the less retained
enantiomer. The enantiomers (S)-38 and (R)-38 were equipotent (EC50 = 0.2 nM, MT-4 infected cells)
against the HIV-1NL4´3 WT strain. Whereas, (R)-38 was more potent than (S)-38 against the HIV-1
mutant strains K103N (EC50 = 0.2 nM), Y181C (EC50 = 2.1 nM) and K103N-Y181C (EC50 = 150 nM;
EFV: EC50 K103N = 130 nM; EC50 Y181C = 160 nM, EC50 K103N-Y181C >317) [94]. Compound (R)-38
was remarkably superior to NVP and EFV, and superior to AZT against the WT, K103N, and Y181C
strains. Docking experiments showed some significant differences in the binding modes (R)-38 and
(S)-38 in the NNBS of the HIV-1 K103N mutated RT. The methyl group of (R)-38 pointed toward the
cleft created by the K103N mutation, sealing the binding pocket and reducing the solvent-accessible
surface, while the corresponding group of the (S)-38 enantiomer left the pocket more exposed to
solvent. Molecular dynamics simulation showed stable trajectories for both enantiomers. However,
calculation of the solvent-accessible surface area (SASA) [94] showed significant differences for the
K103N RT/(S)-38 and K103N RT/(R)-38 complexes. In particular, SASA of the receptor in complex
with the (S) enantiomer was greater than the corresponding one for the (R) enantiomer, reporting
values of 235.64 and 210.20 Å2, respectively. Inside the NNBS the (S) enantiomer showed a number of
water molecules surrounding the methyl cleft, 3.5 times greater than the number of solvent molecules
observed for the (R) enantiomer. These results provided a justification for the different biological
activity observed between (R)-38 and (S)-38 (Scheme 11) [93].
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9. API
A new series of arylphosphoindole (API) derivatives was designed by Idenix Laboratories by
replacing the 3-sulfonyl bridging group of IAS NNRTIs with a phosphinic acid methyl ester group [95].
Compound API 39 as a racemic mixture showed low nanomolar activity against the HIV-1 WT,
K103N, Y181C strains and reasonable activity against the HIV-1 K103N-Y181C double mutant strains
(Scheme 12). Chiral separation of the racemate 39 by supercritical fluid chromatography (SFC) afforded
the enantiomers (R)-39a and (S)-39b. The analytical separation was performed on Chiralcel OD-H
(250 mm ˆ 4.6 mm) column using n-heptane/ethanol/diethylamine 70/30/0.1 as the mobile phase,
flow rate 1.0 mL/min. At preparative level was used a Chiralpak AD (250 mm ˆ 20 mm) column
with CO2/MeOH + 1% diethylamine 80/20 as the mobile phase, flow rate 60 mL/min., flow rate
62 mL/min. The enantiomer 39a was superior to the racemate 39 against the HIV-1 WT and the mutant
viruses (HIV-1 WT, EC50 = 0.1 nM; K103N, EC50 = 1.2 nM, Y181C, EC50 = 3.6 nM; K103N-Y181C,
EC50 = 137.4 nM, MT-4 infected cells). In contrast, 39b was remarkably less potent against HIV-1 WT
and did not inhibit the HIV-1 NNRTI drug-resistant strains. The stereochemistry 39a was assigned to be
(R) according to molecular modeling studies (binding energy: 39a =´23 kcal/mol; 39b: ´18 kcal/mol).
The (R) stereochemistry of 39a was confirmed using X-ray crystallography diffraction.
Scheme 12. Arylphosphoindole (API) derivatives.
In order to achieve broad spectrum against the HIV-1 drug resistant mutant strains, Idenix
introduced the Z-cyanovinyl typical in RPV at position 31 of the 3-phenyl ring of API derivatives.
Among these compounds, the enantiomer (R)-40a (IDX 899) (Scheme 12) potently and selectively
inhibited HIV-1 WT and NNRTI drug resistant HIV-1 mutant strains in vitro, and was selected for
clinical studies. In 2009, Idenix granted GlaxoSmithKline exclusive worldwide rights to IDX 899.
Preclinical data for IDX-899 suggested a significantly greater barrier to resistance compared with EFV.
IDX 899 effectively reduced HIV-1 RNA levels and increased CD4+ cell counts in treatment-naïve
patients infected with HIV-1 during phase I clinical trials [96].
Separation of the racemic (R,S)-carboxylic acids 41 was performed on hundred grams scale by a
two steps procedure to obtain the required enantiomer [96]. Treatment of 41 with (´)-cinchonidine in
acetone furnished the corresponding diastereomeric mixture. The precipitated solid was isolated
by filtration. The filtrate was concentrated, and both solid and residue from the filtrate were
cleaved with 1 N HCl and ethyl acetate. The overall recovery of enantiomeric pure acid was
70%. An alternate separation of the racemate 41 was performed using (1R,2S)-ephedrine and
(1S,2R)-ephedrine monohydrate in ethanol. The basis of this separation was the same as that described
with (´)-cinchonidine.
The enantiosynthesis [97] of IDX 899 required the preparation of menthyl phosphinate
compound from aryl halides or triflates 42 in the presence of Mg or RLi and PCl3 to give
dichlorophosphite derivative 43. Treatment of 43 with (+)- or (´)-menthylchloroformate 44 in
pyridine according to the Hewitt [98] reaction afforded a mixture of diastereoisomers which
was separated into 45a and 45b by crystallization at low temperature in hexane. Reaction of
45a with ethyl 3-bromo-5-chloro-1-phenylsulfonyl-1H-indole-2-carboxylate (46) in the presence of
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tris(dibenzylideneacetone) dipalladium(0)-chloroform adduct (Pd2dba3¨CHCl3) and triethylamine
afforded 47. Reaction of 47 with trimethyloxonium tetrafluoroborate (Meerwein salt) and trifluorocaetic
acid with inversion of configuration afforded 48. Finally, ester 48 was transformed into IDX 899 by
reaction with ammonium hydroxide in methanol or hydrolysis of the ester to carboxylic acid with
lithium hydroxide, activation with carbonyl diimidazole as subsequent displacement of the imidazolide
with ammonia (Scheme 13).
Scheme 13. Enantiosynthesis of IDX 899.
10. TFMI
A series of non-racemic trifluoromethylated indoles (TFMIs) were synthesized as HIV-1
NNRTIs and assayed by a TZM-bl cell assay [99]. The TFMIs were synthesized using an
asymmetric Friedel–Crafts reaction of indoles with alkyl trifluoropyruvates catalyzed by C3-symmetric
cinchonine-squaramide (CSCS, 49) organocatalyst that was developed by the same authors [100]
(Scheme 14). The chiral trifluoromethylated indoles were obtained in excellent yield and
enantioselectivity up to >99% ee. With few exceptions, the chirality of the molecules played a key
role on the antiretroviral activity. As HIV-1 inhibitors the (R)-enantiomers were superior to the
corresponding (S)-enantiomers, and the increased activity of the (R)- over the (S)-enantiomer ranged
from 6 to 32-fold. Compound (R)-50, with a 5-NO2 substituent, was the most potent HIV-1IIIB inhibitor
in the TZM-bl cells, with an EC50 value of 19 nM (EFV EC50 = 15 nM), CC50 value of 210.697 µM and SI
(selectivity index, CC50/EC50) value of 11 089, respectively [99].
Scheme 14. CSCS catalyzed enantiosynthesis of (R)-50.
11. Conclusions
Chirality is recognized to considerably affect the pharmacological profile of drugs due to the
highly specific interaction of the ligand with the recognition site. Accordingly, the enantioselectivity
plays an important role for the binding of antiviral agents to HIV-1 RT. Among chiral HIV-1 NNRTIs,
one enantiomer is often superior to its corresponding counterpart against the HIV-1 WT and the HIV-1
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drug resistant mutant strains. This review illustrates the various studies made to investigate the
effect of chirality on the activity of HIV-1 NNRTIs. Chiral HIV-1 NNRTIs were achieved by either
chiral separation or enantiosynthesis. This review may assist in a more in depth understanding of the
mechanism of action of HIV-1 NNRTIs, as well as suggest concepts for the design and synthesis of
new generation HIV-1 NNRTI agents.
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